102 related articles for article (PubMed ID: 38736501)
21. Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations Previously Treated with Platinum-Based Chemotherapy and Immunotherapy.
Goldschmidt JH; Tseng WY; Wang Y; Espirito J; Vasudevan A; Silver M; Kwong J; Shah R; Marrett E
Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38896198
[TBL] [Abstract][Full Text] [Related]
22. Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response.
Hong M; Lee SW; Cho BC; Hong MH; Lim SM; Kwon NJ
Ther Adv Med Oncol; 2024; 16():17588359241254218. PubMed ID: 38779033
[TBL] [Abstract][Full Text] [Related]
23. Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer.
Ma XT; Ou K; Yang WW; Cao BY; Yang L
World J Clin Oncol; 2024 May; 15(5):635-643. PubMed ID: 38835847
[TBL] [Abstract][Full Text] [Related]
24. Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound-guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non-small-cell lung carcinomas on the Biocartis Idylla™ platform.
Haragan A; Lee R
Cytopathology; 2024 May; ():. PubMed ID: 38814131
[TBL] [Abstract][Full Text] [Related]
25. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Boscolo Bielo L; Belli C; Crimini E; Repetto M; Ascione L; Pellizzari G; Santoro C; Fuorivia V; Barberis M; Fusco N; Rocco EG; Curigliano G
Oncologist; 2024 Jun; 29(6):504-510. PubMed ID: 38520742
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study.
Lu S; Guo X; Yang Z; Sun Y; Niu J; Jing X; Zhu H
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38591950
[TBL] [Abstract][Full Text] [Related]
27. The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer.
Tsui DCC; Holt DE; Patil T; Staley A; Gao D; Kavanagh BD; Schenk EL; Rusthoven CG; Camidge DR
Adv Radiat Oncol; 2024 Jul; 9(7):101516. PubMed ID: 38868503
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.
Nassar AH; El-Am E; Denu R; Abou Alaiwi S; El Zarif T; Macaron W; Abdel-Wahab N; Desai A; Smith C; Parikh K; Abbasi M; Bou Farhat E; Williams JM; Collins JD; Al-Hader A; McKay RR; Malvar C; Sabra M; Zhong C; El Alam R; Chehab O; Lima J; Phan M; Dalla Pria HF; Trevino A; Neilan TG; Kwan JM; Ravi V; Deshpande H; Demetri G; Choueiri TK; Naqash AR
JACC CardioOncol; 2024 Feb; 6(1):71-79. PubMed ID: 38510282
[TBL] [Abstract][Full Text] [Related]
29. The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast.
Hirsch FR; Kim C
Oncol Ther; 2024 Jun; 12(2):223-231. PubMed ID: 38536631
[TBL] [Abstract][Full Text] [Related]
30. Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.
Tanvetyanon T; Chen DT; Gray JE
Clin Lung Cancer; 2024 Apr; ():. PubMed ID: 38825406
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma.
Demir T; Araz M; Moloney C; Hendem E; Koçak MZ; Erman M; Baş O; Köstek O; Sever N; Karakaya S; Zeynelgil E; Chung LI; Chae YK
Clin Lung Cancer; 2024 May; ():. PubMed ID: 38871540
[TBL] [Abstract][Full Text] [Related]
32. Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact
Durbin L; Murali B; Li S; Hawthorne S; Clark O
Future Oncol; 2024 May; ():1-13. PubMed ID: 38695478
[TBL] [Abstract][Full Text] [Related]
33. Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy.
Brown LJ; Ahn J; Gao B; Gee H; Nagrial A; Hau E; Silva IPD
Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893255
[TBL] [Abstract][Full Text] [Related]
34. KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J; Romanovsky E; Kirchner M; Neumann O; Blasi M; Schnorbach J; Shah R; Bozorgmehr F; Savai R; Stiewe T; Peters S; Schirmacher P; Thomas M; Kazdal D; Christopoulos P; Stenzinger A
Br J Cancer; 2024 Jun; ():. PubMed ID: 38866964
[TBL] [Abstract][Full Text] [Related]
35. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome.
Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Wheeler D; Arvanitis L; Pillai R; Afkhami M; Chen BT; Sattler M; Erhunmwunsee L; Massarelli E; Kulkarni P; Amini A; Armstrong B; Salgia R
NPJ Precis Oncol; 2024 Jun; 8(1):135. PubMed ID: 38898200
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma.
Shao K; Hao Y; Xu M; Shi Z; Lin G; Xu C; Zhang Y; Song Z
Clin Oncol (R Coll Radiol); 2024 Apr; ():. PubMed ID: 38777703
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory parameters in NSCLC with driver mutation.
Buyukbayram ME; Hannarici Z; Yilmaz A; Turhan A; Caglar AA; Esdur PC; Bilici M; Tekin SB
Lung Cancer Manag; 2024; 13(1):LMT66. PubMed ID: 38818368
[TBL] [Abstract][Full Text] [Related]
38. Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside.
Montoya C; Spieler B; Welford SM; Kwon D; Pra AD; Lopes G; Mihaylov IB
Front Oncol; 2023; 13():1225720. PubMed ID: 38033493
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification.
Fu R; Xiong Y; Cai M; Li F; Chen R; Wu Y; Zhong W
Front Med; 2024 May; ():. PubMed ID: 38805102
[TBL] [Abstract][Full Text] [Related]
40. Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
Kodama H; Murakami H; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ko R; Ono A; Kenmotsu H; Naito T; Matsumoto S; Goto K; Shimizu T; Gon Y; Takahashi T
Thorac Cancer; 2024 Jun; ():. PubMed ID: 38898747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
